Company
iRhythm Technologies
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
12
510(k), De Novo and PMA
Device trials
3
As lead sponsor, any status
Adverse event reports
288
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1
One per recalled product
iRhythm Technologies is on our public-company list (ticker IRTC). Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
IRTC
Nasdaq · iRhythm Holdings, Inc.
Public float
$4.90B
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$747M
Fiscal year ending Dec 31, 2025
Net income
-$44.6M
Fiscal year ending Dec 31, 2025
R&D spending
$84.6M
Fiscal year ending Dec 31, 2025
Cash
$395M
As of Sep 30, 2026
Long-term debt
$652M
As of Sep 30, 2026
Shares outstanding
33.6M
As of Oct 29, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2024 | – | – | – | $661M |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| May 16, 2014 | Equity | $27.3M | $29.5M | 10 | Rule 506(b) | Form D/A ↗Mar 16, 20151 amendment |
| Mar 27, 2013 | Equity | $15.1M | $17.0M | 17 | Rule 506 | Form D ↗Apr 8, 2013 |
| Nov 1, 2012 | Convertible note | $3.5M | $3.5M | 16 | Rule 506 | Form D ↗Nov 13, 2012 |
3 more funding rounds with a free account
Company details
From the company's latest Form D.
- Legal name
- iRhythm Technologies, Inc.
- Headquarters
- San Francisco, California
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1388658 ↗
Executives, directors and promoters
As listed on the latest Form D.
8 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
The 8 newest of 12 since 2015.
- ZEUS Platform (FG0501US)510(k)
K252859 · Decided May 29, 2026 · 262 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
- Zio® monitor (DFG0001)510(k)
K243650 · Decided Aug 15, 2025 · 262 days after receipt
Device type: Recorder, Magnetic Tape, Medical (DSH) · Cardiology
K240177 · Decided Oct 30, 2024 · 281 days after receipt
Device type: Detector And Alarm, Arrhythmia (DSI) · Cardiology
9 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT07205367 · 150 participants · Start Jan 6, 2025 · Primary completion Jul 29, 2025
Device: Zio Monitor · For: Cardiac Arrhythmia
Sites: San Francisco, California; Deerfield, Illinois
NCT07118124 · 36 participants · Start Aug 15, 2025 · Primary completion Sep 26, 2025
Device: Zio monitor · For: Syncope; Pediatric; Congenital Athymia and 3 more
Sites: Washington D.C., District of Columbia; Boise, Idaho; Boston, Massachusetts · 4 sites in all
NCT04056715 · 250 participants · Start Jan 14, 2020 · Primary completion Apr 18, 2022
Device: Zio XT · For: Hypertrophic Cardiomyopathy; Nonsustained Ventricular Tachycardia; Ventricular Tachycardia and 2 more
Sites: Boston, Massachusetts
Reports received
288
Received Nov 1, 2025 to Nov 20, 2026. Includes 2 of another or unstated type.
Malfunction reports
52
18% of reports
Injury reports
233
81% of reports
Death reports
1
0.3% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 61 | 8 | 0 | 0 |
| Jan 24 | 41 | 5 | 4 | 0 |
| Feb 24 | 43 | 5 | 2 | 0 |
| Mar 24 | 49 | 2 | 3 | 0 |
| Apr 24 | 59 | 2 | 0 | 0 |
| May 24 | 63 | 2 | 0 | 0 |
| Jun 24 | 93 | 2 | 3 | 0 |
| Jul 24 | 6 | 7 | 0 | 0 |
| Aug 24 | 15 | 11 | 0 | 0 |
| Sep 24 | 10 | 5 | 0 | 0 |
| Oct 24 | 14 | 9 | 0 | 0 |
| Nov 24 | 5 | 12 | 1 | 0 |
| Dec 24 | 13 | 13 | 1 | 0 |
| Jan 25 | 7 | 15 | 0 | 0 |
| Feb 25 | 6 | 14 | 0 | 0 |
| Mar 25 | 9 | 13 | 1 | 0 |
| Apr 25 | 10 | 18 | 0 | 0 |
| May 25 | 7 | 11 | 0 | 0 |
| Jun 25 | 1 | 17 | 0 | 0 |
| Jul 25 | 8 | 17 | 0 | 0 |
| Aug 25 | 4 | 31 | 0 | 0 |
| Sep 25 | 3 | 29 | 0 | 0 |
| Oct 25 | 2 | 14 | 0 | 0 |
| Nov 25 | 5 | 23 | 0 | 0 |
| Dec 25 | 5 | 39 | 0 | 0 |
| Jan 26 | 10 | 25 | 1 | 0 |
| Feb 26 | 6 | 43 | 0 | 0 |
| Mar 26 | 3 | 30 | 0 | 0 |
| Apr 26 | 9 | 43 | 0 | 0 |
| May 26 | 1 | 25 | 0 | 0 |
| Jun 26 | 9 | 1 | 0 | 0 |
| Jul 26 | 2 | 3 | 0 | 0 |
| Aug 26 | 2 | 1 | 0 | 2 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
- ZIO MONITOR191
- ZIO AT74
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0183-2023 · Started Sep 28, 2022 · Posted by FDA Nov 4, 2022
Reason given: Ambulatory ECG monitoring system labeling update: 1) Clinically actionable arrhythmia notifications delayed until patient registration is complete; 2) Patches limited to 100 symptomatic and 500 asymptomatic wireless transmissions; once the maximum transmission limit is reached for either type, any further...
Cause as FDA categorized it: Device Design · Device type: Detector And Alarm, Arrhythmia (DSI)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.